Literature DB >> 11988528

The cell surface protein Ag43 facilitates phage infection of Escherichia coli in the presence of bile salts and carbohydrates.

Magdalena Gabig1, Anna Herman-Antosiewicz, Marta Kwiatkowska, Marcin Los, Mark S Thomas, Grzegorz Wegrzyn.   

Abstract

It was found that infection of Escherichia coli by bacteriophage lambda is inhibited in the presence of certain bile salts and carbohydrates when cells are in the "OFF" state for production of the phase-variable cell surface protein antigen 43 (Ag43). The inhibition of phage growth was found to be due to a significant impairment in the process of phage adsorption. Expression of the gene encoding Ag43 (agn43) from a plasmid or inactivation of the oxyR gene (encoding an activator of genes important for defence against oxidative stress) suppressed this inhibition. A mutation, rpoA341, in the gene encoding the alpha subunit of RNA polymerase also facilitated phage adsorption in the presence of bile salts and carbohydrates. The rpoA341 mutation promoted efficient production of Ag43 in a genetic background that would otherwise be in the "OFF" phase for expression of the agn43 gene. Analysis of a reporter gene fusion demonstrated that the promoter for the agn43 gene was more active in the rpoA341 mutant than in the otherwise isogenic rpoA(+) strain. The combined inhibitory action of bile salts and carbohydrates on phage adsorption and the abolition of this inhibition by production of Ag43 was not restricted to lambda, as a similar phenomenon was observed for the coliphages P1 and T4.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11988528     DOI: 10.1099/00221287-148-5-1533

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  16 in total

Review 1.  Phase and antigenic variation in bacteria.

Authors:  Marjan W van der Woude; Andreas J Bäumler
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

2.  A Serratia marcescens OxyR homolog mediates surface attachment and biofilm formation.

Authors:  Robert M Q Shanks; Nicholas A Stella; Eric J Kalivoda; Megan R Doe; Dawn M O'Dee; Kira L Lathrop; Feng Li Guo; Gerard J Nau
Journal:  J Bacteriol       Date:  2007-08-03       Impact factor: 3.490

Review 3.  Type V protein secretion pathway: the autotransporter story.

Authors:  Ian R Henderson; Fernando Navarro-Garcia; Mickaël Desvaux; Rachel C Fernandez; Dlawer Ala'Aldeen
Journal:  Microbiol Mol Biol Rev       Date:  2004-12       Impact factor: 11.056

4.  Modification of Escherichia coli-bacteriophage interactions by surfactants and antibiotics in vitro.

Authors:  Pauline D Scanlan; Anna M Bischofberger; Alex R Hall
Journal:  FEMS Microbiol Ecol       Date:  2016-10-12       Impact factor: 4.194

Review 5.  Survival of the Fittest: How Bacterial Pathogens Utilize Bile To Enhance Infection.

Authors:  Jeticia R Sistrunk; Kourtney P Nickerson; Rachael B Chanin; David A Rasko; Christina S Faherty
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

6.  High diversity among environmental Escherichia coli isolates from a bovine feedlot.

Authors:  Hsiao-Hui Yang; Robert T Vinopal; Domenico Grasso; Barth F Smets
Journal:  Appl Environ Microbiol       Date:  2004-03       Impact factor: 4.792

7.  Virulent bacteriophages can target O104:H4 enteroaggregative Escherichia coli in the mouse intestine.

Authors:  Damien Maura; Matthieu Galtier; Chantal Le Bouguénec; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

8.  Ecological basis for rational phage therapy.

Authors:  A V Letarov; A K Golomidova; K K Tarasyan
Journal:  Acta Naturae       Date:  2010-04       Impact factor: 1.845

9.  STM2209-STM2208 (opvAB): a phase variation locus of Salmonella enterica involved in control of O-antigen chain length.

Authors:  Ignacio Cota; Anne Béatrice Blanc-Potard; Josep Casadesús
Journal:  PLoS One       Date:  2012-05-11       Impact factor: 3.240

Review 10.  Clinical Pharmacology of Bacteriophage Therapy: A Focus on Multidrug-Resistant Pseudomonas aeruginosa Infections.

Authors:  Dana Holger; Razieh Kebriaei; Taylor Morrisette; Katherine Lev; Jose Alexander; Michael Rybak
Journal:  Antibiotics (Basel)       Date:  2021-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.